FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target.

Molecular characterization of breast cancer CTCs associated with brain metastasis. Nat Commun (2017) 1.39

Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19

Molecular portraits of human breast tumours. Nature (2000) 94.14

A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36

NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res (2012) 15.84

Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56

Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70

Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 9.29

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet (2011) 9.20

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol (2008) 6.31

Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol (2010) 5.44

Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol (2008) 5.28

Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62

XIAP discriminates between type I and type II FAS-induced apoptosis. Nature (2009) 3.00

Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol (2008) 2.85

Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med (1996) 2.65

Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science (1998) 2.51

Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol (2004) 2.18

Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res (2008) 2.01

Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell (2001) 1.97

Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med (1997) 1.56

FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol (2003) 1.20

Statistical challenges in preprocessing in microarray experiments in cancer. Clin Cancer Res (2008) 1.19

Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer (2000) 1.08

Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell (2002) 1.06

Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood (1997) 1.04

Regulation of Fas expression by STAT3 and c-Jun is mediated by phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem (2001) 1.04

Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res (2012) 1.02

Statistical considerations for analysis of microarray experiments. Clin Transl Sci (2011) 1.00

Negative regulation of Fas-mediated apoptosis by FAP-1 in human cancer cells. Int J Cancer (2000) 0.94

Normal breast epithelial cells induce apoptosis of breast cancer cells via Fas signaling. Exp Cell Res (2002) 0.94

Preoperative single fraction partial breast radiotherapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys (2010) 0.93

The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast (2007) 0.92

Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death. Free Radic Biol Med (2013) 0.92

FAP-1-mediated activation of NF-kappaB induces resistance of head and neck cancer to Fas-induced apoptosis. J Cell Biochem (2007) 0.90

Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5. Apoptosis (2009) 0.86

Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. PLoS One (2012) 0.85

Radiation-induced effects on gene expression: an in vivo study on breast cancer. Radiother Oncol (2006) 0.82

Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Clin Cancer Res (2004) 0.81

Expression of fas (CD95/APO-1) antigen induced by radiation therapy for diffuse B-cell lymphoma: immunohistochemical study. Clin Cancer Res (1997) 0.80

Tissue expression of the proteins fas and fas ligand in colorectal cancer and liver metastases. J Gastrointest Cancer (2012) 0.78

Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. Radiat Res (2014) 0.77